1. Home
  2. FRSH vs TARS Comparison

FRSH vs TARS Comparison

Compare FRSH & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Freshworks Inc.

FRSH

Freshworks Inc.

HOLD

Current Price

$9.01

Market Cap

2.4B

Sector

Technology

ML Signal

HOLD

Logo Tarsus Pharmaceuticals Inc.

TARS

Tarsus Pharmaceuticals Inc.

HOLD

Current Price

$62.93

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FRSH
TARS
Founded
2010
2016
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.7B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FRSH
TARS
Price
$9.01
$62.93
Analyst Decision
Buy
Buy
Analyst Count
15
6
Target Price
$14.86
$89.00
AVG Volume (30 Days)
9.9M
646.4K
Earning Date
05-05-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
296.88
48.21
EPS
N/A
N/A
Revenue
$838,809,000.00
$451,360,000.00
Revenue This Year
$16.30
$56.43
Revenue Next Year
$14.09
$30.19
P/E Ratio
N/A
N/A
Revenue Growth
16.43
146.71
52 Week Low
$6.79
$38.51
52 Week High
$16.05
$85.25

Technical Indicators

Market Signals
Indicator
FRSH
TARS
Relative Strength Index (RSI) 56.30 46.29
Support Level $7.71 $60.38
Resistance Level $9.29 $67.24
Average True Range (ATR) 0.49 3.60
MACD 0.03 0.28
Stochastic Oscillator 69.75 53.36

Price Performance

Historical Comparison
FRSH
TARS

About FRSH Freshworks Inc.

Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CS and ITSM categories and has also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and serve their customers and employees. The group derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and Other regions. It derives maximum revenue from North America.

About TARS Tarsus Pharmaceuticals Inc.

Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.

Share on Social Networks: